NASDAQ:GRDX Entero Therapeutics (GRDX) Stock Price, News & Analysis $4.97 +0.17 (+3.54%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$4.94 -0.02 (-0.50%) As of 10/9/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC Filings About Entero Therapeutics Stock (NASDAQ:GRDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entero Therapeutics alerts:Sign Up Key Stats Today's Range$4.51▼$5.0450-Day Range$2.74▼$4.9752-Week Range$1.87▼$6.93Volume100,636 shsAverage Volume100,436 shsMarket Capitalization$35.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Entero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for gastrointestinal disorders. The company’s work is centered on treatments intended to address unmet needs in conditions involving inflammation, immune responses and intestinal health. Its lead development program is latiglutenase, an oral enzyme therapy designed to break down immunogenic gluten fragments in the digestive tract. The program is being developed for celiac disease, an autoimmune disorder triggered by gluten exposure. Entero Therapeutics has also pursued gastrointestinal drug candidates, including locally acting formulations intended to treat inflammatory diseases of the intestines. The company’s activities are primarily focused on research and clinical development rather than the sale of marketed products. Its programs are intended for potential use in gastrointestinal conditions affecting patients in the United States and other international markets, subject to successful clinical development and regulatory approval.AI Generated. May Contain Errors. Read More Entero Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreGRDX MarketRank™: Entero Therapeutics scored higher than 14% of companies evaluated by MarketBeat, and ranked 561st out of 598 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Entero Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Entero Therapeutics is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entero Therapeutics is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntero Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.48% of the float of Entero Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntero Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entero Therapeutics has recently increased by 91.76%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntero Therapeutics does not currently pay a dividend.Dividend GrowthEntero Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.39 News SentimentEntero Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Technology companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Entero Therapeutics this week, compared to 0 articles on an average week.Search Interest3 people have searched for GRDX on MarketBeat in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Entero Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.75% of the stock of Entero Therapeutics is held by insiders.Percentage Held by Institutions12.30% of the stock of Entero Therapeutics is held by institutions.Read more about Entero Therapeutics' insider trading history. Receive GRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRDX Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com GRDX Stock Analysis - Frequently Asked Questions How have GRDX shares performed this year? Entero Therapeutics' stock was trading at $2.91 on February 6, 2026. Since then, GRDX stock has increased by 70.8% and is now trading at $4.97. How do I buy shares of Entero Therapeutics? Shares of GRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, GRDX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:GRDX CIK1604191 Webwww.enterothera.com Phone(561) 589-7020FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.39 million Net MarginsN/A Pretax Margin-13,634.24% Return on Equity-47.34% Return on Assets-16.07% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.16 Sales & Book Value Annual Sales$40 thousand Price / Sales885.90 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book0.67Miscellaneous Outstanding Shares7,130,000Free Float7,078,000Market Cap$35.44 million OptionableN/A Beta1.69 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:GRDX) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRDX Stock Alerts